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Abstract: Alagille syndrome is an autosomal dominant, complex multisystem disorder
characterized by the presence of three out of five major clinical criteria: cholestasis with bile
duct paucity on liver biopsy, congenital cardiac defects (with particular involvement of the pulmonary arteries), posterior embryotoxon in the eye, characteristic facial features, and butterfly
vertebrae. Renal and vascular abnormalities can also occur. Inter- and intrafamilial variabilities
in the clinical manifestations are common. We reviewed the clinical features and management
as well as the molecular basis of Alagille syndrome.
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Introduction
Alagille syndrome (ALGS; MIM118450) is a highly variable, autosomal dominant
multisystem condition with an estimated frequency of one in 30,000.1 ALGS is caused
by mutations in one of two genes: JAG1 and NOTCH2. It was initially described as
a hepatic disease, but molecular testing has shown that individuals with ALGS and
JAG1 or NOTCH2 mutations may present without overt liver disease.2,3
ALGS has been defined by a paucity of intrahepatic bile ducts, in association with
at least three of five main clinical abnormalities: cholestasis, cardiac disease, skeletal
abnormalities, ocular abnormalities, and characteristic facial features.2 The cholestasis
is a consequence of the paucity of bile ducts.
The prevalence of ALGS was originally estimated at 1:70,000 live births; however,
this is most likely an underestimation, as cases were ascertained exclusively on the
basis of presence of neonatal liver disease2 and childhood and adult cases without
overt liver disease were not included in this frequency.

Clinical diagnosis and diagnostic criteria
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Traditionally, the clinical diagnostic criteria for ALGS included liver histology showing bile duct paucity (an increased portal tract-to-bile duct ratio) and three of five major
clinical features: cholestasis; ophthalmologic abnormalities (commonly posterior
embryotoxon); characteristic facial features (prominent forehead, deep-set eyes with
moderate hypertelorism, pointed chin, and straight nose with a bulbous tip); cardiac
defect (commonly stenosis of the peripheral/pulmonary arteries); and skeletal abnormalities (commonly butterfly vertebrae).
In addition, abnormalities of the kidneys and vasculature (often in the head and
neck) are important manifestations of ALGS.3–5 These recent observations have led to
75

submit your manuscript | www.dovepress.com

The Application of Clinical Genetics 2016:9 75–82

Dovepress

© 2016 Saleh et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you
hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission
for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

http://dx.doi.org/10.2147/TACG.S86420

Dovepress

Saleh et al

an expansion of the phenotypic criteria of ALGS such that
three of seven characteristic clinical criteria are sufficient
for a clinical diagnosis. Two classic criteria with confirmed
ALGS in a first-degree relative may also be sufficient for
a diagnosis of ALGS. Finally, a liver biopsy is no longer
considered mandatory to make a diagnosis of ALGS, and
the presence of cholestasis is acceptable to fulfill this
criterion.

Systemic manifestations and clinical
description
Disease history and presentation
ALGS is a multisystem disorder with a wide spectrum of clinical variability ranging from life-threatening liver or cardiac
disease to only subclinical manifestations, such as mildly
abnormal liver enzymes, a heart murmur, butterfly vertebrae,
posterior embryotoxon, or characteristic facial features. The
diagnosis may be difficult because of the variable expressivity
of the clinical manifestations.6 This variability is present even
among individuals from the same family sharing the same
mutation.7 In a study of 53 mutation-positive relatives of
affected individuals, 25 (47%) did not meet classic clinical

diagnostic criteria. Thus, without a molecular diagnosis, those
individuals would have likely been missed altogether.7
Disease prognosis and risk of mortality depend on the
severity of organ involvement. Early mortality is typically
caused by cardiac disease or severe liver disease and later
mortality is often caused by vascular accidents.8,9
A few case reports have documented the prenatal findings
in ALGS using a detailed ultrasound scan, including fetal
hemi vertebrae in the lower thoracic region, cardiac changes,
and absent gallbladder, in a fetus with JAG1 mutation10
(Figure 1A–C).
Two studies, one by Emerick et al8 and another by
Subramaniam et al,11 discuss the frequency of clinical
manifestations in individuals with ALGS (Table 1).

Hepatic manifestations
In the majority of cases, individuals with ALGS present in
infancy with cholestasis (conjugated hyperbilirubinemia with
high GGT, increased serum bile acids, and elevated cholesterol and triglycerides), which manifest as jaundice, intense
pruritus, xanthomas (fatty deposits on the extensor surfaces),
and failure to thrive due to fat malabsorption.7,12,13

Figure 1 Prenatal diagnosis of Alagille syndrome.
Notes: (A) A prenatal anatomy scan revealing kyphosis with underlying thoracic vertebral anomaly (blue arrow). (B) A transverse image shows thoracic hemivertebrae
(arrows). (C) A three-dimensional sonogram in the posterior–anterior plane demonstrates classic butterfly and hemivertebrae (arrow).
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Table 1 A summary of the clinical features and the frequency reported among individuals with ALGS
Common system
involved in ALGS

Feature

Overall frequency
in ALGS

Frequency of
finding in
JAG1(+)
ALGS

Frequency of
finding in
NOTCH2 (+)
ALGS

Hepatic

Paucity of biliary duct, conjugated hyperbilirubinemia,
and liver failure
Structural changes, pulmonary stenosis, and tetralogy
of Fallot
Prominent forehead, deep-set eyes with moderate
hypertelorism, pointed chin, and saddle or straight
nose with a bulbous tip
Posterior embryotoxon
Vertebral anomalies (hemivertebra and butterfly
vertebra)
Ureteropelvic obstruction and renal tubular acidosis

Up to 100%

100%

100%

90%–97%, 60%–67%, and
7%–16%
20%–97%

100%

60%

97%

20%

78%–89%
33%–93%

75%
64%

60%
10%

39%

40%

40%

Cardiac
Facial features

Eye
Skeletal
Renal

Abbreviation: ALGS, Alagille syndrome.

A liver biopsy typically shows paucity of the intrahepatic
bile ducts. In newborns with ALGS, bile duct paucity is not
always present and the liver biopsy may demonstrate ductal
proliferation, resulting in the possible misdiagnosis of ALGS
as biliary atresia.
Unremitting cholestasis and progressive liver disease
necessitating liver transplantation occur in ∼15% of individuals with ALGS.8 To date, it has been difficult to predict
which infants will progress to end-stage liver disease. There
are no genotypic, histologic, or radiologic predictors of liver
disease severity. However, a recent study by Mouzaki et al
demonstrated that a high serum total bilirubin between the
ages of 12–24 months combined with fibrosis on liver biopsy
and the presence of xanthomata on physical examination can
predict poor long-term hepatic outcomes in patients with
ALGS12 (Figure 2).

e xamination. Posterior embryotoxon (a prominent Schwalbe’s
ring) is a defect in the anterior chamber of the eye and has
been reported in 78%–89% of individuals with ALGS.8,15
Posterior embryotoxon does not affect visual acuity and has
an incidence of 8%–15% in the general population.
Other ocular defects seen in ALGS include AxenfeldRieger anomaly, which is characterized by an abnormal pupil
that is off-center (corectopia) or by extra holes in the iris that
look like multiple pupils (polycoria).
Ocular ultrasonographic examination in 20 children with
ALGS found optic disk drusen in 90%. Retinal pigmentary
changes are also common (32% in one study).15 Although

Cardiac manifestations
Cardiac findings ranging from benign heart murmurs to significant structural defects occur in 90%–97% of individuals
with ALGS.8,14 The pulmonary vasculature is most commonly
involved. Pulmonic stenosis (peripheral and branch) is the
most common cardiac finding (67%).8 The most common
complex cardiac defect is tetralogy of Fallot, which is seen
in 7%–16% of individuals.8 Other cardiac malformations
include ventricular septal defect, atrial septal defect, aortic
stenosis, and coarctation of the aorta (in order of decreasing
frequency).

Ocular manifestations
The most common ocular finding in individuals with
ALGS is posterior embryotoxon, diagnosed by a slit-lamp

The Application of Clinical Genetics 2016:9
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these changes were initially thought to be the result of dietary
deficiency, they have been seen in individuals with normal
serum concentrations of vitamins A and E.

defects (50%–90%);9,23 and immunodeficiency and recurrent
infections.24

Skeletal manifestations

A few cases of successful pregnancy in AGS have been
described by different groups (Table 2), and stemming from
these cases, several issues should be considered before
attempting embarking on a pregnancy:
• the severity of liver disease and the degree of portal hypertension, which could further worsen during pregnancy;
• the degree of cardiac dysfunction and, in particular, the
severity of pulmonary hypertension; and
• the 50% chance for the fetus to inherit the maternal or
paternal ALGS mutation, although the severity of the
clinical manifestations cannot be predicted in view of the
observed intrafamilial variability.

The most common radiographic finding is butterfly shaped
thoracic vertebrae, secondary to clefting abnormality of
the vertebral bodies. The reported frequency of butterfly
vertebrae ranges from 33% to 93%.9,16,17 Additional skeletal
features include a square shape of the proximal part of the
fingers with tapering distal phalanges and extra digital flexion
creases.18 There also appears to be an increase in pathological
long bone fractures in ALGS, which may be due to cholestasis
and/or an intrinsic defect of the bones.19

Facial features

Pregnancy and ALGS

The pattern of facial features observed in children with ALGS
includes a high forehead with frontal bossing or flattening,
deep-set eyes with moderate hypertelorism, pointed chin, and
saddle or straight nose with a bulbous tip (Figure 3). These
features give the face the appearance of an inverted triangle.
The typical facial features are almost universally present in
ALGS due to JAG1 mutations.1,20 The typical facial features
do not seem to be as prevalent in individuals with ALGS
carrying a NOTCH2 mutation.

Renal abnormalities
Structural renal anomalies, such as small hyperechoic kidney
and renal cysts, as well as functional abnormalities, such
as renal tubular acidosis, have been reported in up to 39%
of individuals with ALGS.4 Hypertension and renal artery
stenosis have also been noted in adults with ALGS.21

Vascular abnormalities
Neurovascular accidents (intracranial bleeding) have been
reported in 15% of ALGS8 and accounted for 34% of mortality in one large study.7 These are potentially devastating
complications, and there are reports of adults with ALGS
with sudden subarachnoid hemorrhage following the rupture
of intracranial aneurysms.22 Renovascular anomalies, middle
aortic syndrome, and other intra-abdominal vascular anomalies have also been reported.21

Additional features
The following additional features have been observed: short
stature: this may be due to poor growth associated with
cholestasis, a severe cardiac defect, and/or intrinsic bone
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Figure 3 Characteristic facial features seen in ALGS.
Notes: Triangular appearance of the face with the high forehead, deep-set eyes with
moderate hypertelorism, pointed chin, and saddle or straight nose with a bulbous
tip. Parental consent was obtained for use of this photograph.
Abbreviation: ALGS, Alagille syndrome.
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Table 2 Case reports of successful pregnancies in mothers with ALGS
Study

LT before
pregnancy

Maternal
age
(years)

Prenatal
counseling

Chorionic
villous
sampling

Delivery
(gestational
week)

Delivery
(technique)

ALGS in
the newborn

Newborn
outcome
at 1 year

Witt et al44
Albayram et al45

No
No

NA
21

Yes
No

Yes
No

NA
35

No
Yes

Herr et al46
Rahmoune et al47
Maisonneuve et al48

No
No
Yes

NA
34
22

NA
Yes
No

NA
No
Yes

36
34
37

NA
Death at
3 months
NA
NA
NA

Jung et al49 (case
series of
four pregnancies)

One out of
four moms

NA

Yes

Yes

NA

NA
Spontaneous
vaginal delivery
Cesarean section
Cesarean section
Elective forceps
delivery
NA

Yes
Yes
Yes
One out of
four newborns

Abbreviations: ALGS, Alagille syndrome; NA, not applicable; LT, liver transplantation.

Thus, genetic counseling is crucial before conception.25 This includes the discussion of preimplantation and
prenatal diagnosis as well as the use of surrogate mother
if the pregnancy can be associated with maternal risk for
deterioration.

Genetics of ALGS
ALGS is caused by mutations in one of two genes: JAG1 and
NOTCH2. Up to 98% are caused by mutations in JAG1 and
2% are caused by mutations in NOTCH2 (Table 3).

JAG1 (chromosome 20p12.2)
JAG1 is a cell surface protein that functions as a ligand for
one of four Notch transmembrane receptors, which are key
signaling molecules in the Notch signaling pathway, an evolutionarily conserved pathway that is crucial in development.
More than 500 pathogenic mutations have been identified
so far in individuals with ALGS. In all, 69% are proteintruncating variants (frameshift and nonsense).26,27

NOTCH2 (chromosome 1p12-p11)
NOTCH2 encodes a member of the Notch family of transmembrane receptors. The Notch receptors (NOTCH1,

NOTCH2, NOTCH3, and NOTCH4 in humans) share
structural characteristics, including an extracellular domain
consisting of multiple epidermal growth factor-like repeats
and an intracellular domain consisting of multiple, different
domain types. The Notch family members play a role in a
variety of developmental processes by controlling cell fate
decisions.
Twelve different pathogenic variants have been identified
in eleven unrelated families with clinical features of ALGS,
including one splice site alteration, one frameshift variant,
one nonsense variant, and seven missense variants.28,29

20p12.2 microdeletion
The presence of developmental delay and/or hearing loss
in addition to the features commonly seen in ALGS may
increase the suspicion of chromosome 20p12.2 interstitial
microdeletion, which encompasses the JAG1 gene (the
ALGS critical region). Kamath et al studied 21 patients with
deletions of the short arm of chromosome 20. Eleven patients
who had normal development with no anomalies outside of
those associated with ALGS had deletions between 95 kb
and 4 Mb. The proximal and distal boundaries of these eleven
deletions constitute a 5.4 Mb region that defines the JAG1-

Table 3 Summary of molecular genetic testing used in ALGS (GeneReviews)
Gene

Proportion of ALGS
attributed to mutation
of this gene

Test method

Mutations detected

JAG1

89%
∼5%–7%

NOTCH2

1%–2%
Unknown

Sequence analysis/mutation scanning
Deletion/duplication analysis
(including FISH and MLPA)
Sequence analysis
Deletion/duplication analysis

Sequence variants
Deletion and duplication of exon(s)
and entire gene deletion
Sequence variants
Unknown, none reported

Abbreviations: ALGS, Alagille syndrome; FISH, fluorescence in situ hybridization; MLPA, Multiplex ligation-dependent probe amplification.
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associated critical region. The other ten patients had bigger
deletions between 3.28 Mb and 14.62 Mb, which extended
outside the critical region, and, notably, all of these patients
had developmental delay and other associated features.30

to a 96% 1-year survival rate for individuals with biliary
atresia. This reduction in survival was attributed to the
vascular and systemic involvement in ALGS.40

Genotype–phenotype correlations

Neurovascular manifestations are treated in a standard
manner. For ALGS individuals with symptomatic moyamoya
disease, revascularization can prevent ischemic events and
neurologic disability. A recent study by Baird et al on a
group of five children with ALGS and symptomatic moyamoya revealed good postsurgical outcomes. These patients
remained clinically and radiologically stroke free during
long-term follow-up despite progression of moyamoya arteriopathy on angiographic studies.41
No cerebrovascular screening guidelines exist for ALGS.
Given this good outcome, it was suggested by Kamath et al
that the same standards of care applied to children with
moyamoya in the absence of ALGS should be applied to
children with ALGS.

No genotype–phenotype correlations exist between the
clinical manifestations of ALGS and the specific JAG1
pathogenic variant types or the location of the mutation
within the gene.31,32 However, two families with JAG1 pathogenic missense variants had cardiac disease without liver
involvement.33,34
Patients with disease-causing variants in NOTCH2 may
have an increased incidence of kidney disease.29 However,
the number of individuals identified with ALGS caused by
mutations of NOTCH2 is still too small to draw conclusions.
In general, understanding the genetic basis of ALGS
has assisted the molecular diagnosis and broadened our
understanding of the phenotype associated with JAG1 and
NOTCH2 mutations. However, a lack of genotype–phenotype
correlations has limited the use of these genetic data to impact
clinical management.

Treatment of manifestations
Given the multisystem involvement of ALGS, patients
with ALGS require evaluation by a multidisciplinary team,
i ncluding specialists in hepatology, medical genetics,
cardiology, nephrology, nutrition, and ophthalmology; liver
transplantation team; neurologists; neurosurgeons; and
specialists in child development depending on the findings.35
Here, we will concentrate on the hepatic and neurovascular
complications of ALGS.

Hepatic manifestations
The liver disease of ALGS typically manifests with
severe debilitating pruritus and disfiguring xanthomas.
The management is largely supportive with choleretic
agents (ursodeoxycholic acid) and other medications
(cholestyramine, rifampin, naltrexone) for the itch. Surgical
biliary diversion procedures (partial internal biliary diversion
and ileal exclusion) have also been used in ALGS to ameliorate itch and xanthomas.36,37 A Kasai procedure (hepatic
portoenterostomy), as used in biliary atresia, seems to worsen
the outcome in ALGS and is therefore not recommended.38
Liver transplantation for ALGS has an 80% 5-year survival rate, and results in some catch-up growth in 90% of
affected individuals.39 Kamath et al showed that the 1-year
survival rate for individuals with ALGS was 87%, compared
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Genetic counseling
ALGS is inherited in an autosomal dominant manner.
Therefore, offspring of an individual with ALGS have a 50%
chance of inheriting the causative gene mutation in the JAG1
or NOTCH2 gene.
In ∼50%–70% of affected individuals, the mutation is
de novo,3 while up to 50% of individuals with ALGS have
an affected parent.
If the proband has an identifiable JAG1 or NOTCH2
pathogenic variant, molecular genetic testing of the parents
is recommended. If the proband shows a microdeletion of
20p12 on fluorescence in situ hybridization (FISH) testing,
FISH testing of both parents is indicated.
If one of the parents is affected, their risk for having an
affected child in their future pregnancies is 50%. However,
when the parents are clinically unaffected, the risk to the
siblings of a proband appears to be low, but multiple instances
of a child inheriting ALGS from an apparently unaffected,
phenotypically normal parent with mosaicism for a 20p
microdeletion have been reported.42 If the JAG1 or NOTCH2
pathogenic variant or deletion present in the proband cannot
be found in either parent, the risk to the siblings is low, but
higher than that of the general population because of the
possibility of germline mosaicism.43

Conclusion
ALGS is a multisystem disorder associated with liver, cardiac,
eyes, face, renal, central nervous, and skeletal abnormalities.

The Application of Clinical Genetics 2016:9

Dovepress

The condition has an autosomal dominant mode of inheritance, and thus, the recurrence risk for an affected person is
50% in each subsequent pregnancy. The mortality is ∼10%,
with vascular accidents, cardiac disease, and liver disease
being the most frequent cause of death. The two causative
genes associated with ALGS are JAG1 and NOTCH2. The
management of an affected patient should be conducted by a
multidisciplinary team, which includes specialists in medical
genetics, gastroenterology, hepatology, nutrition, cardiology,
ophthalmology, nephrology, liver transplantation, and when
necessary, neurosurgery.
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